1. Home /
  2. Drug Approvals

Drug Approvals

Can Legal Cannabis Help Slow the Opioid Drug Epidemic in the U.S.?

Can Legal Cannabis Help Slow the Opioid Drug Epidemic in the U.S.?

More research is needed, but medical experts agree that cannabis plants have immense potential to slow opioid drug overdoses, which claim 115 lives every day in the U.S.

If We Got Boehner, We Can Get Anyone: Washington's Growing Role in Cannabis

If We Got Boehner, We Can Get Anyone: Washington's Growing Role in Cannabis

Cannabis isn't a red and blue issue in Washington. Here's how the political landscape is changing as marijuana prohibition becomes 'politically untenable.'

This Company Is at the Center of Insider Trading Charges Against Rep. Collins

This Company Is at the Center of Insider Trading Charges Against Rep. Collins

Innate Immunotherapeutics of Australia is the biopharmaceutical company at the center of the insider trading charges leveled against New York Rep. Chris Collins.

Jim Cramer on Johnson & Johnson's Pharmaceuticals Sales Growth

Jim Cramer on Johnson & Johnson's Pharmaceuticals Sales Growth

When investors review a drug company, pay close attention to its pharma performance, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.

Cannabis Firm Canopy Growth Deserves a Premium but Still a Sell, Analysts Say

Cannabis Firm Canopy Growth Deserves a Premium but Still a Sell, Analysts Say

A wider-than-expected quarterly loss has Echelon Wealth Partners cautious on Canopy.

Weed Sales in Canada Could Top $7 Billion After Full Legalization This Summer

Weed Sales in Canada Could Top $7 Billion After Full Legalization This Summer

Nearly two-thirds of cannabis consumers will transition to legal channels and subsequently pay more, according to a new study from Deloitte.

U.S. Markets 'Definitively' Missing Out on Capital by Barring Cannabis Companies

U.S. Markets 'Definitively' Missing Out on Capital by Barring Cannabis Companies

The U.S. markets are missing out on the rise of the cannabis industry, according to several experts TheStreet talked with on the topic.

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Jim Cramer and our other experts discuss oil prices, bullish market signals and medical diagnostic plays.

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.

Trump Administration Rolls Out Shaming as Drug Pricing Tool

Trump Administration Rolls Out Shaming as Drug Pricing Tool

When President Trump gave a speech on prescription drug pricing last week, many were disappointed pharmaceutical companies seemed to escape his wrath. The answer seems to be shame.